<DOC>
	<DOCNO>NCT01242488</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics , immunogenicity CDP6038 treatment adult subject active rheumatoid arthritis inadequate response anti-tumor necrosis factor ( anti-TNF ) therapy .</brief_summary>
	<brief_title>Efficacy Safety CDP6038 Patients With Rheumatoid Arthritis With Unsuccessful Response Anti-Tumor Necrosis Factor ( Anti-TNF ) Therapy</brief_title>
	<detailed_description>CDP6038 protein ( antibody ) block interleukin-6 ( IL-6 ) , substance involve inflammation associate rheumatoid arthritis . This multicenter , 12-week , randomize , double-blind , placebo- active- control study compare several dos dosage regimen ( every 2 week every 4 week ) CDP6038 placebo tocilizumab patient active rheumatoid arthritis unsuccessful response methotrexate previous anti-TNF therapy . The study test CDP6038 efficacious placebo reduce sign symptom rheumatoid arthritis 12 week maintain adequate safety profile . In order maintain study blind subject give subcutaneous ( sc ) injection ( skin ) every 2 week , well intravenous ( iv ) infusion every 4 week . In addition subject must remain stable weekly dos methotrexate . Assessments study include evaluation joint pain swelling , laboratory blood urine test , physical examination , vital sign , electrocardiogram , questionnaire . Subjects complete 12-week study eligible enroll long-term extension study receive CDP6038 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have diagnosis rheumatoid arthritis ( accord 1987 ACR classification criterion OR score ≥6 define ACR/European League Against Rheumatism Classification Diagnostic Criteria rheumatoid arthritis ) least 6 month prior screen Must treat MTX 12.525 mg/week , least 6 week prior screen . Doses 10 &lt; 12.5mg/week allow document intolerance Have moderately severely active rheumatoid arthritis disease least 6 tender 6 swollen joint CRP ≥1.2 time upper limit normal ( central laboratory ) erythrocyte sedimentation rate 28mm/hour Intolerant inadequate response treatment ( ie , TNF blocker failure ) ≥1 license TNFblocker therapy within 2 year screen Have diagnosis inflammatory arthritis secondary , noninflammatory type arthritis , psoriatic arthritis , lupus , gout , ankylose spondylitis Wheelchair bound bedridden . Disease modify antirheumatic drug ( DMARDs ) MTX . Treatment tocilizumab antiIL6 investigational therapy time . Treatment biologics within 424 week ( depend biologic ) History ongoing , chronic recurrent infection recent serious lifethreatening infection Known concurrent acute chronic viral hepatitis B C infection human immunodeficiency virus ( HIV ) infection . Vaccinations ( injectable influenza pneumococcal ) within 8 week prior screen plan receive vaccine study Concurrent history malignancy exception nonmelanoma skin cancer successfully treat 2 year prior screen cervical cancer successfully treat 5 year prior screen . History chronic alcohol abuse drug addiction within last 1 year current drug addiction use illicit drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CDP6038</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Tocilizumab</keyword>
</DOC>